Skip To Main Content
View US Healthcare Professionals Site

*On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.

Why VABYSMO might be right for you

Icon - eye

Improves vision quickly*

Icon - double-check

It’s the only FDA-approved treatment thought to block 2 causes of DME†

Icon - 4-treatment

Delivers a chance for up to 4 months between treatments‡

*On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.
†VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
‡After 4 or 6 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response. Dosing may vary.
Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.

†VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
‡After 4 or 6 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response. Dosing may vary.
Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.

Discover how VABYSMO could Open Up Your World

Open Transcript

Male Narrator: How did I get here, king of the grill and the goal?  It started when VABYSMO opened up my world. 

Male Narrator: Losing my sight due to DME worried me. 

Super: Diabetic Macular Edema (DME).

Male Narrator: But thanks to VABYSMO I have improved vision. I’m still in the game. 

Super: VABYSMO IMPROVES VISION QUICKLY On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.

Male VO: Ask a retina specialist about VABYSMO.

IMPORTANT SAFETY INFORMATION

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

  • Have an infection in or around your eye.

  • Have active swelling around your eye that may include pain and redness.

  • Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

  • Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.

  • VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.

  • Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.

  • Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.

  • Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.

  • Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO?

  • Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.

What are the most common side effects with VABYSMO?

  • The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).

  • These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.

VABYSMO and the VABYSMO logo are registered trademarks of Genentech, Inc.

© 2025 Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990.

All rights reserved.

M-US-00027370(v1.0) 09/25

 

What is VABYSMO?

Learn about the science behind how VABYSMO works

Discover more

Treatment with VABYSMO

Explore clinical trial results and what to expect from treatment

See the difference

Financial support

Find out how you could save on your VABYSMO, even if you have no health insurance

Explore our options

“VABYSMO has given me a second chance.”


Nina

VABYSMO patient
Watch the full story

Patient experiences may vary. Patient compensated by Genentech.

NEXT: What is DME?

Diabetic macular edema (DME) is a complication of diabetes, caused by fluid buildup and swelling in the retina that can damage vision. Without proper treatment, DME can severely impact visual clarity.

VABYSMO (faricimab-svoa) is approved to treat DME. It’s thought to block 2 causes of vision loss (VEGF and Ang-2),‡ proteins that drive abnormal blood vessel swelling, leakage, and growth. The benefit of blocking Ang-2 has yet to be established. It also improves vision quickly.† On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.

VABYSMO is given by injection into the eye. Initial dosing will be every 4 weeks, then dosing is determined by your doctor based on how you respond. You may be able to go up to 4 months between treatments.§

The possible serious side effects of VABYSMO were inflammation and detached retina (separation of the retina from the back of the eye); a temporary increase in eye pressure; although not common, there is a risk of a stroke or heart attack; severe inflammation of vessels in the retina. These are not all the possible side effects of VABYSMO.

IMPORTANT SAFETY INFORMATION

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

  • Have an infection in or around your eye. 
  • Have active swelling around your eye that may include pain and redness. 
  • Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

  • Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
  • VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
  • Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
  • Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
  • Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
  • Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO? 

  • Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.

What are the most common side effects with VABYSMO?

  • The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
  • These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555. 

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.